Multiple sclerosis: pharmacogenomics and personalised drug treatment

被引：0
|
作者：
V. Annibali
G. Ristori
S. Cannoni
S. Romano
A. Visconti
A. Ghazaryan
L. Figà Talamanca
M. Salvetti
R. Mechelli
机构：
[1] Ospedale S. Andrea,Department of Neurology and Centro Neurologico Terapia Sperimentale (CENTERS)
[2] University of Rome “La Sapienza”,undefined
来源：
Neurological Sciences | 2006年 / 27卷
关键词：
Pharmacogenomics; Multiple sclerosis; Therapy; Microarrays;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Multiple sclerosis (MS) is a disorder of the central nervous system with an inflammatory and a neurodegenerative component. We do not yet have a definitive therapy for MS. Attempts to develop new treatments are long and costly and should be paralleled by studies aimed at increasing the therapeutic index of the existing treatments, interferon β and glatiramer acetate. Pharmacogenetics and pharmacogenomics may be of use in this respect though their application may not be straightforward, particularly in MS.
引用
收藏
页码：s347 / s349
相关论文
共 50 条
  • [31] Pharmacogenomics and Multiple Sclerosis: Moving Toward Individualized Medicine
    Comabella, Manuel
    Vandenbroeck, Koen
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2011, 11 (05) : 484 - 491
  • [32] Pharmacogenomics and Multiple Sclerosis: Moving Toward Individualized Medicine
    Manuel Comabella
    Koen Vandenbroeck
    Current Neurology and Neuroscience Reports, 2011, 11 : 484 - 491
  • [33] United Europeans for development of pharmacogenomics in multiple sclerosis network
    Vandenbroeck, Koen
    Comabella, Manuel
    Tolosa, Eva
    Goertsches, Robert
    Brassat, David
    Hintzen, Rogier
    Infante-Duarte, Carmen
    Favorov, Alexander
    Escorza, Sergio
    Palacios, Ricardo
    Oksenberg, Jorge R.
    Villoslada, Pablo
    PHARMACOGENOMICS, 2009, 10 (05) : 885 - 894
  • [34] Perspective of personalised drug treatment in depression
    Ising, M.
    Scheuer, S.
    Belcredi, P.
    Uhr, M.
    Holsboer, F.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S46 - S47
  • [35] Integrating pharmacogenomics into personalized drug treatment
    Ingelman-Sundberg, M.
    Ingelman-Sundberg, M.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 1070 - 1071
  • [36] Repurposing the multiple sclerosis drug Siponimod for osteoporosis treatment
    Hu, Sitao
    Hu, Yangyang
    Tan, Zenglin
    Zhou, Chengyu
    Zhang, Cheng
    Yin, Sheng
    Chen, Xiaojun
    Chen, Kai
    Wang, Lu
    Chen, Lei
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2024, 974
  • [37] Immunomodulatory Drug Treatment in Multiple Sclerosis: Effect on Survival
    Orion, David
    Chapman, Joab
    Dolev, Mark
    Tsabari, Rakefet
    Achiron, Anat
    NEUROLOGY, 2009, 72 (11) : A241 - A241
  • [38] Drug treatment of multiple sclerosis - Clinical review was unsystematic
    Milne, R
    Clegg, A
    Bryant, J
    BRITISH MEDICAL JOURNAL, 2001, 322 (7281): : 299 - 299
  • [39] Funding of drug treatment of multiple sclerosis should not be delayed
    Paty, DW
    BRITISH MEDICAL JOURNAL, 1997, 315 (7116): : 1160 - 1161
  • [40] Advancing drug delivery systems for the treatment of multiple sclerosis
    Inna Tabansky
    Mark D. Messina
    Catherine Bangeranye
    Jeffrey Goldstein
    Karen M. Blitz-Shabbir
    Suly Machado
    Venkatesh Jeganathan
    Paul Wright
    Souhel Najjar
    Yonghao Cao
    Warren Sands
    Derin B. Keskin
    Joel N. H. Stern
    Immunologic Research, 2015, 63 : 58 - 69
12345